Last reviewed · How we verify
NCT06146205: HIFSAT
The Hip Fracture Surgical Approach Trial
NA trial testing Direct lateral approach in Hip Fracture in 476 participants. Participants enrolled and being followed up; not accepting new ones.
30 August 2026
Quick facts
| Lead sponsor | Diakonhjemmet Hospital |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 476 |
| Start date | 30 April 2024 |
| Primary completion | 30 August 2026 |
| Estimated completion | 30 March 2028 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- Direct lateral approach
- SPAIRE
Conditions studied
- Hip Fracture — all drugs for Hip Fracture →
- Femoral Neck Fracture — all drugs for Femoral Neck Fracture →
Sponsor
Diakonhjemmet Hospital
Who can join
50 and older, any sex, with Hip Fracture or Femoral Neck Fracture. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The HIFSAT study will compare the standard direct lateral approach to hemiarthroplasty to a new muscle sparing approach (SPAIRE) in femoral neck fracture patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06146205
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Direct lateral approach
Trials testing the same drug.
- NCT04870151 — Anterolateral Versus Direct Lateral Approach in Hemiarthroplasty for Hip Fracture · NA · active not recruiting
Other recruiting trials for Hip Fracture
Currently open trials in the same condition.
- NCT07481188 — Frailty and Nottingham Hip Fracture Score for Predicting 90-Day Mortality After Hip Fracture Surgery · recruiting
- NCT07113483 — Remimazolam vs. Midazolam for Sedation and Cognitive Outcomes in Orthopedic Surgery · Phase 3 · recruiting
- NCT06898814 — The Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery · Phase 4 · recruiting
- NCT06818409 — Is the CRP-Albumin-Lymphocyte (CALLY) Index Effective in Predicting Postoperative Delirium in Geriatric Patients Undergo · recruiting
- NCT07202208 — Effectiveness of the Delirium Zero Protocol to Prevent the Onset of Delirium in Patients Undergoing Hip Fracture Surgery · NA · recruiting
Other Diakonhjemmet Hospital trials
Trials by the same sponsor.
- NCT07003932 — Remote Monitoring After Total Knee Replacement · NA · recruiting
- NCT06656845 — Feasibility of a Self-management App for People With Knee Osteoarthritis (OA-AID Feasibility Study) · NA · completed
- NCT07106931 — Early STratification of Acute ARThritis · recruiting
- NCT06440629 — Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Ar · Phase 4 · recruiting
- NCT06281184 — A 30-month Follow-up of MERINO Participants to Evaluate Long-term Effects of Methotrexate in Erosive Hand OA. · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06146205 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Diakonhjemmet Hospital
- Last refreshed: 30 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06146205.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing